Sign in
4

Changes in Ownership

Lineage Cell Therapeutics, Inc. Filed Acc 0001209191-16-151321

Options or other derivatives

  • Sr VP, Head of Corporate Dev acquired 300,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

KNIGHT JAMES A. · Sr VP, Head of Corporate Dev

Table II: Derivative

1 line
Date Transaction Shares Exercise Expires Underlying Owned after D/I
2016-10-19 Grant or award : show line 1 in the form Option to Purchase Common Shares +300,000 $3.49 2026-10-18 300,000 300,000 D
Loading xslF345X03/doc4.xml…